Le Lézard
Classified in: Health
Subject: SVY

Human Liver Models Market Worth 2.56 Billion USD by 2022


PUNE, India, April 26, 2018 /PRNewswire/ --

According to a new market research report "Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022", published by MarketsandMarketstm, the global market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022). The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Browse 7 market data Tables and 2 Figures spread through 37 Pages and in-depth TOC on "Human Liver Models Market"

https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market-171046468.html

Early buyers will receive 10% customization on this report 

Animal models accounted for the largest share of the market in 2017 

The Human Liver Models Market is segmented on the basis of type into liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. In 2017, the animal models segment accounted for the largest share of the global market. The growth in the biosimilars market is expected to boost the preclinical market as the development of biosimilars and biopharmaceuticals requires an understanding of the mechanism of action, quantification of pharmacological effects, and interpretation of toxicological data. Preclinical research also helps in securing a clear definition of targets. Moreover, as the patents for many blockbuster drugs are set to expire by 2020, the demand for biosimilars and preclinical services is likely to increase. The rising demand for preclinical services, in turn is expected to drive the demand for animal models.

Ask for PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=171046468

North America held the largest share of the market in 2017 

In 2017, North America accounted for the largest share of the Human Liver Models Market, followed by Europe. 

The market for human liver models in this region is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, favorable government initiatives, growing incidence of NAFLD, and unavailability of livers for transplantation, increased research spending, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.

The key players in the global Human Liver Models Market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).

Know more about the Human Liver Models Market: 

https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market-171046468.html

About MarketsandMarketstm  

MarketsandMarketstm provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarketstm for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarketstm are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarketstm now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarketstm is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Salgarkar
MarketsandMarketstm INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets


These press releases may also interest you

at 17:55
Asia Green Biotechnology Corp. ("Asia Green" or the "Company") announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the...

at 17:53
The following statement is being issued by Rice Harbut Elliott LLP regarding the Ruckman v. Biotrade Canada Ltd. et al. lawsuit: All persons in Canada who purchased or ingested U-Dream on or after August 18, 2014 (the "Class" or "Class Members")...

at 17:49
BioVaxys Technology Corp. (FRA: 5LB) (the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of...

at 17:33
The American Association of Kidney Patients (AAKP), the oldest and largest independent kidney patient consumer organization in the United States, announced the overwhelming success of its 2024 "Are You O-K+" campaign, which marked May 1 (5.1) as...

at 17:21
The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotechnology, announced a strategic partnership to develop and commercialize cutting-edge tools to expedite antibody discovery and...

at 17:00
Zepp Health Corporation ("Zepp" or the "Company") , a global leader in smart wearables and health technology, today announced that it has received a letter from the New York Stock Exchange (the "NYSE") dated April 30, 2024, notifying Zepp that it is...



News published on and distributed by: